Akorn — Investor Presentation (April 2020)
66 slides from Akorn's investor presentation, Apr 22, 2020
Slide 1: Overview Presentation April 15, 2020
OVERVIEW PRESENTATION April 15, 2020
Slide 2: Presentation limitations
By reading or reviewing the presentation slides, you agree to be bound by the following limitations . This presentation has been prepared for informational and background purposes only and the information contained herein (unless otherwise indicated) has been provided by Akorn, Inc . (together with
Slide 3: Disclaimer
Disclaimer This presentation includes statements that may constitute “forward - looking statements,” including expectations regarding the Com pany’s business, the path and milestones for executing a sale of the Company’s business, through the filing of Chapter 11 cases under the U.S. Bankruptcy Code
Slide 4: S&P Capital IQ notice
This presentation may include information from the S&P Capital IQ Platform Service . Such information is subject to the following : “Copyright © 2020 , S&P Capital IQ (and its affiliates, as applicable) . This may contain information obtained from third parties, including ratings from credit ratings
Slide 5: Recipient confidentiality and use of information
By accepting this presentation, the recipient agrees to use the information herein in accordance with its compliance policies, contractual obligations (including, but not limited to, the provisions of that certain confidentiality agreement entered into between the recipient and Akorn, Inc . (the “Co
Slide 6: Table of Contents
Table of Contents 1. Executive Summary 7 2. COVID - 19 Update 17 3. Products and Pipeline Overview 20 4. Manufacturing Overview 28 5. Quality Update 31 6. 5 - Year Forecast 38 7. Q1 2020 Estimate 50 8. 13 Week Cash Flow Forecast 53 9. Appendix 57 6
Slide 7: Executive Summary
OAKORN Executive Summary
Slide 8: Akorn Overview
Akorn Overview Overview and Key Facts 1 ▪ Akorn, Inc. (“Akorn” or the “Company”) specializes in difficult - to - manufacture sterile and non - sterile alternate dosage forms including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays ▪ Akorn operates through two seg
Slide 9: Akorn Management Team
Akorn Management Team Douglas Boothe President and CEO 18 years in pharma. Prior experience: Impax, Perrigo, Actavis Duane Portwood EVP and CFO 4 years at Akorn. Prior experience: Home Depot, Wrigley, PwC Greg Lawless EVP, Chief Human Resources Officer 4 years at Akorn. Prior experience: Altria, Kra
Slide 10: Akorn is a Leading Specialty Pharma Player in Attractive Niche Markets
Akorn is a Leading Specialty Pharma Player in Attractive Niche Markets Diversified Product Portfolio Strong Product Pipeline and R&D Capabilities Strong Growth Forecast with High Operating Leverage and Cash Flow Generation Potential Experienced Management Team ▪ Specialty generics business focused o
Slide 11: Akorn is Executing a Significant Turnaround
Akorn is Executing a Significant Turnaround Initial steps have been taken to stabilize the business and focus on long - term profitable growth ▪ Strengthening the foundation and improving operational results ▪ Improving financial results and cash flow generation ▪ Increasing R&D efficiency and bolst
Slide 12: Akorn stabilized its operations in 2019 and strengthened its foundation
$682 $120 2019A $ in millions Akorn stabilized its operations in 2019 and strengthened its foundation 1 Further Adjusted EBITDA as used in this presentation is defined as net (loss) income (minus) plus (i) depreciation expense, ( ii) amortization expense, (iii) interest expense, net, (iv) income tax
Slide 13: Near-Term Focus Areas
Stabilize Operations Optimize In - Line Portfolio Performance Invest in New Product Development and Pipeline Near - Term Focus Areas ▪ Stabilize and improve manufacturing, quality, and compliance while limiting introduction of new operational risks ▪ Complete cGMP improvements across facilities ▪ Ta
Slide 14: Operational Initiatives Yielding Value
Operational Initiatives Yielding Value Financial results improving with operational performance and improved customer service. Increased Product Availability Improved Operational Performance 5 Product Approvals in 2019 Significant Cost Savings Progressing with FDA Action Items at Decatur and Somerse
Slide 15: Where Akorn is Going
Where Akorn is Going ▪ Akorn is positioned for revenue and Further Adj. EBITDA growth, with an expected revenue CAGR of 7% for FY19 - FY24 • Growth driven by new product launches as well as a moderate increase in branded products, partially offset by forecast declin es in base business • Product lau
Slide 16: Foundation for Success
Foundation for Success Fundamental strengths provide a growth platform upon which to build Diversified Product Portfolio Strong Growth Potential Operational Efficiencies Experienced Management Team Strong Product Pipeline and R&D Capabilities Favorable Market Dynamics 16
Slide 17: COVID-19 Update
OAKORN ~ 5 COVID-19 Update
Slide 18: Akorn's Pandemic Response
Prevent Respond Communicate Akorn’s Pandemic Response Akorn implemented a proactive, multi - faceted plan to protect employees while continuing its operations. Highlights of the plan are detailed below. ▪ COVID - 19 education and health monitoring guidance ▪ Thermal scanning camera at facility entra
Slide 19: Potential Impact of COVID-19
People Operations Financials Potential Impact of COVID - 19 ▪ Key focus on employee health and safety ▪ Closely monitoring plant personnel to reduce risk of transmission and ensure adequate staffing ▪ Adequate supplies of PPE currently on - hand, monitoring stocks for potential shortfalls ▪ Producti
Slide 20: Products and Pipeline Overview
Confidential Products and Pipeline Overview
Slide 21: Diverse Specialty Pharma Offering
Retail Diverse Specialty Pharma Offering Generic Prescription Branded Ophthalmics Consumer Health Animal Health Retail Retail ▪ Broad and diverse portfolio of ~150 products ▪ Products across variety of alternative dosage forms ▪ High barriers to entry ▪ Strong presence in both retail and institution
Slide 22: Eye Care
EYE CARE
Slide 23: Key Products
Key Products Note: Products listed in alphabetical order. Lidocaine Jelly TheraTears Atropine Zioptan Myorisan AK - Fluor Phenylephrine Loteprednol Dorzolamide - Timolol 23
Slide 24: Product Groups – Annual Trends
Product Groups – Annual Trends 24 Akorn’s product portfolio encompasses diverse offerings across multiple dosage forms. No single product has represented more than 10% of annual revenue since 2017, nor is forecasted to do so in the future. Net Sales ($ in millions) 1 FY 2018A FY 2019A FY 2020F Produ
Slide 25: Overview of Pending ANDAs
Overview of Pending ANDAs Current pipeline of ANDAs represent a total market opportunity of $5.8bn, with significant diversification by dosage form and manufacturing site. Note: Pending ANDA counts as of 3/31/20 including tentatively approved ANDAs. Market size is based on IQVIA data for 12 month s
Slide 26: Active Development Pipeline and R&D Investment
$38 $44 $46 $35 $40 $40 $41 $42 $42 0% 1% 2% 3% 4% 5% 6% 7% 8% 2016A 2017A 2018A 2019A 2020F 2021F 2022F 2023F 2024F % of Revenue Active Development Pipeline ▪ R&D spend targeted on ophthalmics and animal health products ▪ Project selection considers product segment and manufacturing location divers
Slide 27: New Product Revenue Provides Significant Growth
New Product Revenue Provides Significant Growth ▪ Business plan includes risk adjusted revenues and contribution margins for products pending approval and in development ▪ Ophthalmic capabilities enable production of more complex products 27 New Product Revenue by Current Status ($ in millions) $12
Slide 28: Manufacturing Overview
Manufacturing Overview
Slide 29: Global Manufacturing and R&D Infrastructure
Decatur, IL Sterile Injectables and Ophthalmics Global Manufacturing and R&D Infrastructure 1 The Company continues to explore strategic alternatives to exit its facility in Paonta Sahib, India. Cranbury, NJ Research & Development Amityville, NY Sterile Ophthalmic Solutions & Suspensions and Non - S
Slide 30: Global Manufacturing Operation Details
Global Manufacturing Operation Details Facility Last FDA Inspection (Results) Core Capabilities Headcount (12/31/19) % Net Sales (2020F) Amityville, NY February 2019 (VAI) Oral liquids in bottles and unit dose cups, topical gels, creams , ointments , nasal sprays, prescription , OTC, and controlled
Slide 31: Quality Update
OAKORN ¢ . oJ é a Quality Update
Slide 32: Quality Enhancements Overview
Quality Enhancements Overview Akorn has completed a substantial majority of the 400+ FDA compliance - related action items; Remaining action items to be completed in 2020 ▪ In 2018, the FDA conducted multi - week inspections at the Company’s Decatur and Somerset facilities • The FDA issued Forms 483
Slide 33: Quality System Corrective Action Plan (QSCAP)
Quality System Corrective Action Plan (QSCAP) Akorn submitted its formal QSCAP governance program document to the FDA in June 2019. • FDA inspectional findings since Jan 2017 • Other regulatory and external audit findings since Jan 2017 • Data Integrity Action Plan initiated in March 2018 • Other th
Slide 34: Major Site Activities Completed
Major Site Activities Completed Akorn has made substantially completed its 483 and Warning Letter action items. Below are several major site specific activities completed. Site Major Site Remediation Activities Completed Action Item Completion Stats 1 Decatur x Installation of RABS across multiple l
Slide 35: Global Implementation of Major Initiatives
Global Implementation of Major Initiatives Taking a global approach to addressing observations, Akorn has enhanced practices across the manufacturing network and R&D facilities Summary of Major Action Areas Decatur Somerset Amityville Hettlingen Vernon Hills Cranbury Aseptic Practice Assessment / Tr
Slide 36: Status by Facility
Status by Facility Facility Last FDA Inspection (Results) Comments Hettlingen, Switzerland February 2020 (Form 483; 3 observations) ▪ Feb 2020 inspection with three Form 483 observations related to training, procedures and batch records; 483 response submitted in Mar 2020 ▪ SwissMedic audit July 201
Slide 37: Non-Recurring Data Integrity and Remediation Spending
Non - Recurring Data Integrity and Remediation Spending ($ Millions) 2018A 2019A 2020F Data Integrity Consulting / Legal 28 12 – Total Data Integrity 28 12 – Remediation Consulting 21 31 9 Remediation Teams (Internal) 1 2 2 Method Remediation (Internal) – 2 3 Total Remediation 22 35 14 Total Remedia
Slide 38: 5-Year Forecast
OAKORN 5-Year Forecast
Slide 39: Business Plan Summary
Business Plan Summary Stabilization in 2019 is providing a foundation to improve profitability through operational improvement initiatives and new product launches. 1 For the definition of Further Adjusted EBITDA, see footnote 1 on page 12. Reconciliation of GAAP Net (Loss) to non - GAAP EBITDA, Adj
Slide 40: Revenue Overview
$981 $712 $555 $525 $531 $508 $481 $448 $431 $136 $130 $139 $146 $164 $173 $181 $180 $177 $12 $65 $145 $241 $297 $331 $1,117 $841 $694 $682 $760 $825 $904 $924 $939 2016A 2017A 2018A 2019A 2020F 2021F 2022F 2023F 2024F Base Business Brands New Products Revenue Overview ▪ Historical erosion in base b
Slide 41: 2020 Net Revenue: Key Drivers vs. 2019
2020 Net Revenue: Key Drivers vs. 2019 ($ in millions) 41
Slide 42: Further Adjusted EBITDA Bridge: 2018 to 2019
Further Adjusted EBITDA Bridge: 2018 to 2019 2019 Further Adjusted EBITDA increased by $40mm compared from 2018. ($ in millions) For the definition of Further Adjusted EBITDA, see footnote 1 on page 12. Reconciliation of GAAP Net (Loss) to non - GAAP EBITDA, Adjusted EBITDA and Further Adjusted EBIT
Slide 43: Further Adj. EBITDA Bridge: 2019 to 2020F
Further Adj. EBITDA Bridge: 2019 to 2020F 2020F improvement over 2019 driven by new product introductions, operational improvements and the annualization of 2019 actions. ($ in millions) For the definition of Further Adjusted EBITDA, see footnote 1 on page 12. Reconciliation of GAAP Net (Loss) to no
Slide 44: Further Adj. EBITDA Bridge: 2018A – 2024F
Further Adj. EBITDA Bridge: 2018A – 2024F Adjusted EBITDA growth driven by production stability, new products and operational improvements. ($ in millions) For the definition of Further Adjusted EBITDA, see footnote 1 on page 12. Reconciliation of GAAP Net (Loss) to non - GAAP EBITDA, Adjusted EBITD
Slide 45: Key Assumptions: Revenue
Key Assumptions: Revenue ▪ Represents currently marketed products that are subject to brand or generic competition ▪ Includes formerly high - value / high market share products, such as Ephedrine, Clobetasol and Lidocaine Ointment ▪ Major products reviewed individually and trends adjusted accordingl
Slide 46: Key Assumptions: Operations & Expenses
Key Assumptions : Operations & Expenses ▪ Plan includes network optimization costs for ophthalmic products: • Tech transfer costs of $4 - 6 million per year included in plan • Capital investments for plant modernization projects to ensure long - term stability of production of transferred products P
Slide 47: Key Assumptions: Operations & Expenses, cont.
Key Assumptions : Operations & Expenses, cont. ▪ Non - recurring external costs related to data integrity and FDA remediation (excluded from Further Adjusted EBITDA) • $ 14 million of 2020 costs related to remediation ▪ Normal run rate costs included in project expenses in 2021 – 2024 (included in F
Slide 48: Adjusted P&L Summary
Actuals Forecast ($ in millions) 2016 2017 2018 2019 2020 2021 2022 2023 2024 Net Revenue $1,117 $841 $694 $682 $760 $825 $904 $924 $939 Gross Margin $674 $432 $246 $253 Adjusted Gross Margin 1 $685 $445 $278 $294 $364 $415 $469 $515 $524 % of Net Revenue 61.3% 52.9% 40.0% 43.1% 47.9% 50.3% 51.9% 55
Slide 49: Cash Flow Summary
Cash Flow Summary The Company is projected to generate significant cash flow in the forecast period. Note: Projections of Net (Loss) Income and Net cash (used in) provided by operating activities are not provided herein because such figures are no t available on a forward - looking basis and reconci
Slide 50: Q1 2020 Estimate: P&L and Cash Flow
Q1 2020 Estimate: P&L and Cash Flow
Slide 51: Q1 2020 Estimate vs Forecast
Q1 2020 Estimate vs Forecast Q1 2020 preliminary result estimates are in line with forecast Note: Results presented are a preliminary estimate, not final, reviewed or audited and are not reconciled to the nearest GAAP nu mber as the financial close process is not yet complete. Estimates and forecast
Slide 52: Q1 2020 Estimate Cash Flow Summary
Q1 2020 Estimate Cash Flow Summary Decrease in cash during Q1 2020 driven by the restructuring process and working capital ($ in millions) Estimated increase in accounts receivable = ($37) Reduction in accounts payable = ($14) Other = $2 Note : Results presented are a preliminary estimate, not final
Slide 53: 13 Week Cash Forecast
OAKORN 13 Week Cash Forecast:
Slide 54: 13 Week Cash Flow Forecast: Key Assumptions
13 Week Cash Flow Forecast: Key Assumptions Items Methodology Overall Methodology • Receipts and disbursement projections for US Debtors aligned to the 2020 forecast, adjusted to reflect the following: o Impacts of actual results o Known changes in operations and timing o Restructuring process relat
Slide 55: 13 Week Cash Flow Forecast
13 Week Cash Flow Forecast (US$ '000) Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 11 Week 12 Week 13 Total Week Beginning: 3/30/20 4/6/20 4/13/20 4/20/20 4/27/20 5/4/20 5/11/20 5/18/20 5/25/20 6/1/20 6/8/20 6/15/20 6/22/20 6/29/20 4/6/20 Week Ending: 4/5/20 4/12/20 4/
Slide 56: Long-term Cash Flow Forecast
Long - term Cash Flow Forecast April May June July August Total (US$ '000) 5 Weeks 4 Weeks 4 Weeks 4 Weeks 5 Weeks 22 Weeks Week Beginning: 3/30/20 5/4/20 6/1/20 6/29/20 7/27/20 3/30/20 Week Ending: 5/3/20 5/31/20 6/28/20 7/26/20 8/30/20 8/30/20 Status: Forecast Forecast Forecast Forecast Forecast F
Slide 57: Appendix
OAKORN 5 obwetcomed ; a im Appendix
Slide 58: Organizational Chart
CEO Finance Quality R&D Commercial Operations Corporate Strategy/Development/ Investor Relations Legal/Compliance Regulatory Affairs Human Resources IT Organizational Chart New Hire Project Management 58
Slide 59: Management Team Overview
Management Team Overview Joined Akorn in 2019 Douglas Boothe – President and Chief Executive Officer Mr. Boothe, was named President and Chief Executive Officer of Akorn as of January 1, 2019. Prior to joining Akorn, Boothe mo st recently served as president of the generics division of publicly held
Slide 60: Jonathan Kafer – Chief Commercial Officer
Jonathan Kafer – Chief Commercial Officer Mr. Kafer joined Akorn in April 2015 as Executive Vice President, Sales and Marketing. Mr. Kafer was appointed the Chief Comm erc ial Officer of Akorn in December 2018. He joined Akorn from Allergan, Inc., where he was previously the Vice President, Account
Slide 61: Erislandy (Dandy) Dorado-Boladeres – EVP, Global Quality
Erislandy (Dandy) Dorado - Boladeres – EVP, Global Quality Mr. Dorado was appointed Executive Vice President, Global Quality, effective March 25, 2019. Mr. Dorado brings decades of pha rma ceutical experience to Akorn having most recently been Vice President of Quality Affairs at American Regent, wh
Slide 62: Jennifer Bowles – SVP, Corporate Strategy and Investor Relations
Jennifer Bowles – SVP, Corporate Strategy and Investor Relations Since joining Akorn in July 2012, Mrs. Bowles has been actively engaged in developing and leading Akorn’s corporate vision and strategic priorities. Responsible for corporate development, portfolio selection, corporate strategy and inv
Slide 63: Greg Lawless – EVP, Chief Human Resources Officer
Greg Lawless – EVP, Chief Human Resources Officer Mr. Lawless joined Akorn in January 2016 from The Kraft Heinz Company, where he was most recently the Vice President, Human R eso urces for Global Operations. In that role, Mr. Lawless was the HR leader for the integration of the Operations function
Slide 64: Reconciliation of GAAP Gross Margin to Adjusted Gross Margin and R&D
Reconciliation of GAAP Gross Margin to Adjusted Gross Margin and GAAP R&D Expense to Adjusted R&D Investment 64 Year Ended December 31, December 31, December 31, December 31, $ in millions 2016 2017 2018 2019 $674 $432 $246 $253 India related expense 10 11 8 4 Non-cash stock compensation expense 1 2
Slide 65: Reconciliation of GAAP Operating Income (Loss) To Adjusted Operating Income
Reconciliation of GAAP Operating Income (Loss) To Adjusted Operating Income 65 65 Year Ended December 31, December 31, December 31, December 31, $ in millions 2016 2017 2018 2019 $323 ($23) ($388) ($188) Non-cash stock compensation expense 15 21 22 21 Impairment of intangible assets 44 128 231 29 Im
Slide 66: Reconciliation of GAAP Net (Loss) to Adjusted EBITDA and Further Adjusted EBITDA
Reconciliation of GAAP Net (Loss) to Adjusted EBITDA and Further Adjusted EBITDA 66 66 Year Ended December 31, December 31, December 31, December 31, December 31, $ in millions 2015 2016 2017 2018 2019 $151 $184 ($25) ($402) ($227) Interest expense, net 52 43 38 46 69 Amortization expense 66 66 61 5